Latest Sales Performance News

Me Today Limited’s China partner has increased its ownership in the Me Today China trademark to 40% after hitting key revenue targets, reflecting growing traction in the Chinese sports nutrition market.

Acrux has locked in a milestone-based licensing agreement worth up to AUD 5.4 million for Lenzetto®, targeting the Australian menopause therapy market with regulatory and commercial milestones tied to TGA approval and sales performance.

Immuron Limited has responded to an ASX price query following a sharp rise in its share price and trading volume, confirming no undisclosed information but pointing to a recent CEO presentation as a possible driver.

UOA Development Bhd’s Q1 2026 results reveal a decline in revenue and profit compared to last year, despite a solid RM130.7 million in new property sales and a substantial unbilled sales pipeline.

Super Retail Group reports a subdued second half in FY26 with 0.4% like-for-like sales growth, impacted by geopolitical tensions and inflation, while costs rise to $66 million due to accelerated projects.

JB Hi-Fi posted modest sales growth in Australia and The Good Guys during Q3 FY26, while New Zealand sales declined amid rising supplier costs and stock shortages heading into a critical trading period.

Mirvac Group reported robust operational results in 3Q26, driven by a 28% jump in residential sales, high occupancy across its investment portfolio, and a successful $630 million capital raise for its wholesale office fund. The company reaffirmed its FY26 guidance amid cautious risk management.

BPH Global has secured a key coastal site in South Sulawesi to boost its seaweed cultivation and processing capabilities, underpinning its vertical integration strategy across food and bio stimulant markets.

Freehill Mining’s aggregate materials sales surged in March, with quarterly sales up 60%, while the company prioritises mine planning and permitting for its Blanco y Negro copper-gold project.

Ryman Healthcare’s FY26 retirement living sales hit 1,410 ORAs, aligning with guidance despite a Q4 dip in new sales. The company reports robust aged care occupancy and expects free cash flow near NZD 180 million.

Mesoblast Limited (ASX:MSB, Nasdaq:MESO) has received FDA Investigational New Drug clearance to initiate a pivotal clinical trial of its cell therapy Ryoncil in children with Duchenne Muscular Dystrophy, aiming to address inflammation-driven disease progression.

Mesoblast Limited (ASX:MSB, Nasdaq:MESO) reported net sales of US$30.3 million for its FDA-approved cellular therapy Ryoncil in the March quarter, bringing total revenue since launch close to US$100 million. Strong sales in February and March offset January’s seasonal dip.